Research Supported by Biopharmaceutical Companies Boosts Economy, Benefits Local Patients


Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation

10.25.13 | By

Alzheimer’s has proven to be a stubborn, puzzling and perhaps even symbolic disease. In recent years, it has emerged as one of our greatest tests of biopharmaceutical science because of the disease’s vast and growing impact on the health of our aging population and the viability of our health care system.

Maximizing Prescription Quality Through ePrescribing

10.24.13 | By

Today, PhRMA will be hosting a stakeholder action group meeting with the National Council for Prescription Drug Programs (NCPDP) called “Maximizing Prescription Quality Through ePrescribing.” NCPDP is a non-for-profit, American National Standards Institute (ANSI) certified standards development organization.

Advancing Cancer Research

10.24.13 | By

How can we continue to advance cancer research and improve patient outcomes in an era of cost containment?  The issue was recently highlighted in a New York Magazine article that only provided part of the story on cancer progress and cost containment.  Last week I had the opportunity to tackle this question as part of a roundtable that convened leaders from across the cancer community.

Institute of Medicine National Academy of Sciences

The Fight Against Cancer

10.22.13 | By

According to the American Cancer Society, nearly one of every two people will develop a cancer at some point in their life.

California's Fight Against Obesity

10.22.13 | By

Today, I’ll be speaking to state-wide leaders in California regarding the state’s fight against obesity.

Immeasurable Benefits for Research

10.22.13 | By

This year, biopharmaceutical companies committed to transforming how their clinical research can be used to advance innovation for patients through careful sharing of clinical trial data with independent researchers. 

Addressing Obesity in America: Economics & Impact on Diverse Patient Communities

10.22.13 | By

The Partnership to Fight Chronic Disease
Addressing Obesity in America: Economics & Impact on Diverse Patient Communities
John J. Castellani, President & CEO, Pharmaceutical Research and Manufacturers of America
Los Angeles, CA
October 22, 2013

Thank you, Ken, for that kind introduction.

Greater collaboration is key to improving patient outcomes

10.21.13 | By

More than 30 million Americans suffer from rare diseases – conditions that are classified as such because they affect fewer than 200,000 people in the United States. Fortunately, there are more than 450 new medications in the pipeline to treat these conditions, and one-third of all new drug approvals over the last five years have been for medicines specific to rare diseases.


Subscribe to RSS - Opinion